UroGen Pharma Ltd.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-153.5M | $-126.9M | $-102.2M | $-109.8M | $-110.8M | $-128.5M | $-105.1M | $-75.7M |
| Depreciation & Amortization | $307.0K | $329.0K | $802.0K | $924.0K | $831.0K | $416.0K | $300.0K | $400.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $12.0M | $13.1M | $9.3M | $10.6M | $23.1M | $28.0M | $30.0M | $30.6M |
| Net Cash from Operating Activities | $-162.4M | $-96.8M | $-76.4M | $-87.6M | $-84.9M | $-105.9M | $-71.0M | $-37.3M |
| Investing Activities | ||||||||
| Capital Expenditures | $289.0K | $295.0K | $194.0K | $254.0K | $752.0K | $1.2M | $325.0K | $560.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $61.6M | $-20.6M | $-953.0K | $1.1M | $4.1M | $93.2M | $-145.6M | $35.3M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $39.9M | $194.6M | $116.9M | $97.1M | $72.3M | $16.5M | $165.3M | $66.4M |
| Net Change in Cash | $-61.0M | $77.2M | $39.6M | $10.6M | $-8.5M | $3.9M | $-51.4M | $64.4M |
| Free Cash Flow | $-162.7M | $-97.1M | $-76.6M | $-87.8M | $-85.6M | $-107.1M | $-71.3M | $-37.9M |